Athena Vale
Pseudohypertrophy, or false enlargement, is a condition in which the size of a muscle increases due to the infiltration of fat or connective tissue, rather than an increase in muscle tissue. This can give the appearance of enlarged muscles, commonly associated with Duchenne muscular dystrophy. However, the muscle is actually atrophied and weaker. Pseudohypertrophy is typically caused by diseases affecting the muscle or the nerve supplying it. It is important to distinguish pseudohypertrophy from true muscle hypertrophy, as the underlying causes and treatments differ.
| Characteristics | Values |
|---|---|
| Definition | Pseudohypertrophy, or false enlargement, is an increase in the size of an organ due to infiltration of a tissue not normally found in that organ. |
| Muscle Pseudohypertrophy | Commonly applied to enlargement of a muscle due to infiltration of fat or connective tissue. |
| Muscle Hypertrophy | The muscle tissue itself increases in size. |
| Muscle Pseudohypertrophy vs Muscle Hypertrophy | In pseudohypertrophy, the muscles look bigger but are actually atrophied and thus weaker. |
| Causes | Muscle diseases: dystrophinopathies, limb-girdle muscular dystrophies, metabolic myopathy, Dystrophic myotonias, endocrine disorders, parasitic muscle conditions, amyloid and sarcoid myopathy, and granulomatous myositis. |
| Other Names | Muscular steatosis, pseudohypertrophic atrophy, lipomatous pseudohypertrophy, interstitial lipomatosis, lipomatous muscular dystrophy, or atrophia lipomatosa. |
| Exceptions | Not all muscles infiltrated by fat or other tissue are pseudohypertrophic. |
Explore related products
What You'll Learn
- Pseudohypertrophy is commonly associated with Duchenne muscular dystrophy
- It is caused by the infiltration of fat or connective tissue
- It is a result of muscle disease or a disease of the nerve supplying the muscle
- Myotilinopathies are a group of muscle disorders caused by mutations in the MYOT gene
- Pseudohypertrophy is also known as muscular steatosis, lipomatous pseudohypertrophy, interstitial lipomatosis, and lipomatous muscular dystrophy
Pseudohypertrophy is commonly associated with Duchenne muscular dystrophy
Pseudohypertrophy is the appearance of enlarged muscles, which are eventually replaced by fat and connective tissue. It is commonly associated with Duchenne muscular dystrophy (DMD), a genetic disorder characterised by progressive muscle degeneration and weakness. DMD is caused by a defective gene for dystrophin, a protein that helps keep muscle cells intact. The condition primarily affects boys, with onset usually occurring between the ages of 2 and 6.
DMD is one of four conditions known as dystrophinopathies, which are a spectrum of muscle diseases caused by alterations in the dystrophin gene. The other three diseases in this group are Becker muscular dystrophy (BMD), a mild form of DMD with a slower disease course; an intermediate clinical presentation between DMD and BMD; and DMD-associated dilated cardiomyopathy, which involves little to no clinical skeletal or voluntary muscle disease.
Pseudohypertrophy is often observed in the muscles of the calves, buttocks, and shoulders of individuals with DMD. This enlargement of the muscles is one of the early signs of the disease, typically appearing around age 4 or 5. As DMD progresses, muscle weakness and atrophy spread to other areas of the body, including the pelvic area, shoulders, trunk, and forearms.
The disease is progressive, and most individuals with DMD require a wheelchair by their teenage years. Currently, there is no known cure for DMD, but treatments aim to control symptoms and improve quality of life. Steroid drugs, for example, can be used to slow the loss of muscle strength. In the future, stem cell and gene therapies may also be utilised.
Muscles: A Complex Organ of Discrete Power Units
You may want to see also
Explore related products
It is caused by the infiltration of fat or connective tissue
Pseudohypertrophy, or false enlargement, is the increase in the size of an organ due to the infiltration of tissue that is not normally found in that organ. Pseudohypertrophy is commonly associated with the enlargement of a muscle due to the infiltration of fat or connective tissue. This is in contrast to typical muscle hypertrophy, where the muscle tissue itself increases in size.
Muscles affected by pseudohypertrophy appear bigger but are weaker due to atrophy. Pseudohypertrophy is often the result of a disease, such as dystrophinopathies, limb-girdle muscular dystrophies, metabolic myopathy, dystrophic myotonias, endocrine disorders, amyloid, and sarcoid myopathy. For example, in muscular dystrophy, the replacement of muscle tissue with fat tissue leads to atrophy of the muscle, while the fat tissue replaces the bulk, causing the appearance of enlarged muscles.
In some cases, muscles infiltrated by fat or other tissue may not exhibit pseudohypertrophy. In muscular steatosis, for instance, the muscles may appear normal or slender, despite the infiltration of fat tissue. Similarly, in myosclerosis, the muscle is infiltrated with connective tissue and fibrosis, resulting in a firm, "woody" feel, but the muscles appear slender rather than enlarged.
The presence of pseudohypertrophy can be evaluated through physical examination and imaging techniques such as magnetic resonance imaging (MRI). MRI scans can reveal fatty infiltration in muscles, which is indicative of pseudohypertrophy. This information can then be used to inform treatment plans and management strategies for the underlying condition causing the pseudohypertrophy.
Calisthenics: Muscle Builder or Just a Fad?
You may want to see also
Explore related products
It is a result of muscle disease or a disease of the nerve supplying the muscle
Pseudohypertrophy, or false enlargement, is the increase in the size of an organ due to the infiltration of tissue that is not normally found there. Pseudohypertrophy is typically the result of a disease, which can be a disease of muscle or a disease of the nerve supplying the muscle.
Muscle pseudohypertrophy is commonly associated with the infiltration of fat or connective tissue, as seen in Duchenne muscular dystrophy. This is in contrast to typical muscle hypertrophy, where the muscle tissue itself increases in size. In muscular dystrophy, the muscles look bigger but are actually atrophied and weaker. Denervation of a muscle usually leads to atrophy with fatty replacement, but in some cases, it can also result in pseudohypertrophy.
Myotilinopathies are a group of muscle disorders caused by mutations in the MYOT gene. They can present as a generalized symmetrical increase in muscle bulk, leading to a Herculean appearance, as well as muscle weakness and stiffness in the lower extremities. MRI scans show extensive fatty infiltration in the thigh and leg muscles.
Other causes of muscle pseudohypertrophy include dystrophinopathies, limb-girdle muscular dystrophies, metabolic myopathy, dystrophic myotonias, endocrine disorders, parasitic muscle conditions, amyloid and sarcoid myopathy, and granulomatous myositis. In some cases, muscle pseudohypertrophy may be associated with diabetic neuropathy or hypothyroidism.
Do Muscles Make Women Tick?
You may want to see also
Myotilinopathies are a group of muscle disorders caused by mutations in the MYOT gene
Muscle pseudohypertrophy refers to a group of muscle disorders caused by mutations in the MYOT gene, otherwise known as myotilinopathies. Myotilinopathies were first described in two families suffering from limb girdle muscle dystrophy type 1 (LGMD 1A). They were later identified in a subset of dominant or sporadic patients suffering from myofibrillar myopathy, as well as in a family with spheroid body myopathy.
The disease phenotypes associated with MYOT mutations are clinically diverse and include pure LGMD forms as well as late-onset distal myopathies. One case study reported on a 53-year-old male suffering from a unique clinical profile characterised by a generalised symmetrical increase in muscle bulk, resulting in a Herculean appearance. The patient's main complaints were muscle weakness and stiffness in the lower extremities. A muscle MRI revealed extensive fatty infiltration in the thigh and leg muscles, and a muscle biopsy showed a myofibrillar myopathy with prominent protein aggregates.
Myotilinopathies are associated with structural changes in Z-discs and the formation of polymorphic aggregates. Z-discs are important for maintaining myofibril architecture, as well as signalling, mechanosensing, and mechanotransduction. Myotilin is a component of Z-disc proteins and is encoded by the MYOT gene on chromosome 5q31.2. It has a molecular weight of 57 kDa and is exclusively expressed in skeletal and cardiac muscle.
The Ser55Phe myotilin mutation has been identified in several cases of late-onset distal myopathy and two cases of late-onset proximal weakness. This mutation can result in a hypertrophic appearance and a myopathic pattern in EMG, despite normal muscle strength. The presence of this mutation in asymptomatic individuals suggests that myotilinopathies may be autosomal dominant.
In summary, myotilinopathies are a group of muscle disorders caused by mutations in the MYOT gene, which encodes the myotilin protein. These mutations can lead to structural changes in Z-discs and result in a range of clinical manifestations, including muscle pseudohypertrophy, weakness, and stiffness. Further research is needed to better understand the role of autophagy in myotilinopathy and to develop effective treatments.
Origin of Piriformis Muscle: The S2 Connection
You may want to see also
Pseudohypertrophy is also known as muscular steatosis, lipomatous pseudohypertrophy, interstitial lipomatosis, and lipomatous muscular dystrophy
Pseudohypertrophy, or muscle pseudohypertrophy, is a condition where there is an apparent enlargement of the muscles that may be due to underlying neuromuscular weakness. It is not true muscle enlargement. Pseudohypertrophy is also known as muscular steatosis, lipomatous pseudohypertrophy, interstitial lipomatosis, and lipomatous muscular dystrophy.
Interstitial lipomatosis (IL) refers specifically to the presence of adipose tissue in the myocardium, or muscular tissue of the heart. A study of diseased and transplanted hearts found that only grade 2 interstitial lipomatosis was considered potentially pathological.
Lipomatous muscular dystrophy refers to the replacement of muscle by adipose and fibrous tissue. This is observed in limb-girdle muscular dystrophy (LGMD), which is characterised by progressive weakness of proximal muscles.
Lipomatous hypertrophy of the atrial septum (LHAS) is a rare, benign heart anomaly characterised by an infiltration of adipocytes into myocytes of the interatrial septum, giving a characteristic hourglass-shaped image. It can cause unexpected problems during cardiac surgery, such as technical difficulties with bicaval cannulation and visualisation of the operated structures of the heart.
Muscle Soreness: Friend or Foe?
You may want to see also
Frequently asked questions
Muscle pseudohypertrophy, or false enlargement, is an increase in the size of a muscle due to infiltration by fat or connective tissue. This is different from muscle hypertrophy, where the muscle tissue itself increases in size.
Muscle pseudohypertrophy is typically caused by a disease, which can be a disease of the muscle or a disease of the nerve supplying the muscle. Causes include dystrophinopathies, limb-girdle muscular dystrophies, metabolic myopathy, Dystrophic myotonias, endocrine disorders, and amyloid and sarcoid myopathy.
Muscle pseudohypertrophy is typically diagnosed through a physical examination, which may include a muscle biopsy and imaging techniques such as MRI to detect fatty infiltration in the muscles.
